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Abstract
Continuous glucose monitoring (CGM) provides an instantaneous real-time display of glucose
level, rate of change of glucose, alerts, and alarms for actual or impending hypo- and
hyperglycemia. Continuous glucose monitors are able to stay implanted on the patient anywhere
from 7-14 days, giving patients and doctors valuable information to help improve patient care for
diabetics, and providing them with a way to continuously monitor their blood glucose level
concentration throughout the day.
Conventional methods of glucose detection such as blood glucose meters require the patient to
gather frequent blood samples to generate instantaneous results that are only accurate as of the
time of day the reading was taken. These methods fail to take account of daily fluctuations in
glucose levels that can arise from changes in diet and physical activity.
In an effort to optimize cost, reliability, and accessibility, this paper proposes a minimally
invasive continuous glucose monitoring system that is able to detect glucose levels in interstitial
fluid through the use of solid 3D printed microneedles. This CGM device would provide an
easily affordable, accessible, and pain-free option for diabetic patients. Providing patients with a
way to continuously monitor their glucose levels allows for more personal involvement with
their health decisions and ultimately serves as a guide toward more effective diabetes
management.
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Chapter 1: Introduction

1.1 Introduction
According to the Centers of Disease Control and Prevention (CDC), roughly 37.3 million people
in the United States have diabetes (11.3% of the population); 28.7 million people, including 28.5
million adults are diagnosed with diabetes, and 8.5 million people are thought to be undiagnosed.
Furthermore, in total, 96 million people aged 18 years or older have prediabetes (38% of the
adult US population), and 26.4 million people aged 65 years or older (48.8%) have prediabetes
[1]. Diabetes is also one of the leading causes of death in the United States, according to the
American Diabetes Association, in 2019 diabetes was the seventh leading cause of death in the
United States based on the 87,647 death certificates in which diabetes was listed as the
underlying cause of death [2].
There are two types of diabetes, type 1 and type 2, that occur when the body is unable to store
and utilize insulin effectively. This causes glucose to stay in the blood, making it hard for the
body’s organs to generate the energy needed to function normally. Limited energy sources can
lead to heart disease, vision loss, extreme fatigue, neuropathy, and kidney disease [2].
Of all diagnosed diabetes cases, 5.8% were type 1 [3]. Although type 1 diabetes affects all age
groups, the majority of individuals are diagnosed either at around the age of 4 to 5 years or in
their early teens and early adulthood. Type 1 diabetes results from an autoimmune disease
associated with the selective destruction of insulin-producing pancreatic β-cells that prevent your
body from producing insulin [4]. The low insulin levels make it harder for your body to regulate
blood glucose levels. Patients with type 1 diabetes must receive insulin from an outside source
every day in order to regulate their blood glucose levels.
Type 2 diabetes is the predominant form of diabetes and accounts for at least 90% of all cases of
diabetes [5]. Type 2 diabetes is caused by the inability of insulin-target tissues to respond
properly to insulin. It can be caused over time due to unhealthy eating and exercise habits. The
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main way to treat type 2 diabetes is through losing weight, eating healthier foods, and staying
physically active [6].
For patients with type 1 and type 2 diabetes, it is important to regularly monitor their glucose
levels. Understanding how one’s blood glucose levels fluctuate throughout the day allows
patients and doctors to better prepare treatments and lifestyle changes to manage diabetes.
1.2 Background
Continuous glucose monitoring (CGM ) systems represent an important advance in diabetes
technology that can facilitate optimal glucose control in type 1 and type 2 diabetes. Continuous
glucose monitors allow for hundreds of readings per day that display real-time glucose levels,
fluctuation rates, and directionality of glucose levels [7]. Using a small patch to obtain
continuous glucose readings makes it easier, less painful, and more accessible for patients with
diabetes. Users will no longer have to prick their fingers for blood samples that are only accurate
as of the time they collected that sample. Continuous glucose monitors enable diabetic patients to
gain a better understanding of how their glucose levels fluctuate throughout the day, and as a
result, they gain a better understanding of how to change their lifestyle to better treat their form
of diabetes.
Our goal is to build a minimally invasive CGM system through the use of microneedles, which
are able to penetrate a few hundred micrometers into the skin. Using microneedles should reduce
the amount of pain and swelling, minimize the risk of infection, and provide more accurate
glucose readings compared to current CGM devices on the market. While current systems on the
market penetrate the subcutaneous layer, our system will penetrate into the dermal layer of the
skin as shown in figure 1-1, measuring glucose concentration in interstitial fluid.

9

Figure 1-1: Layers of the Skin
1.3. Current CGM Devices on the Market
There are currently multiple continuous glucose monitors available on the market. Most CGM
devices are electrochemical sensors that detect glucose concentration in blood samples. For these
CGM devices, the sensor needle tip penetrates into the subcutaneous level of the skin, where it
measures the glucose concentration in blood. Insertion of these glucose sensing needles and
electrodes through the epidermis and dermis into the subcutaneous tissue damages cells,
connective tissue, and extracellular matrix. These devices are often reported as invasive and
associated with discomfort for the patients, which are potential limitations to continuous and
consistent use of the device. They also have relatively high drop-out rates within their clinical
studies [8].
The most commonly used CGM devices in the US are the Abbott Freestyle Libre, the Dexcom
G6, and the Medtronic Guardian Connect. All three of these devices penetrate into the
subcutaneous tissue where glucose concentration is measured in blood plasma. Medtronic’s
Guardian Connect is injected into the subcutaneous layer and is considerably painful for patients
to use [8]. Compared to typical single-use glucose sensors, these devices offer the ability to
provide continuous data for up to 2 weeks. This can be extremely beneficial for doctors to help
create a better treatment plan for that particular patient. Although it is better to be able to
continuously monitor glucose concentrations throughout an entire day with minimal handling,
10

the fact of the matter is these devices are still not widely used. This can be due to the high cost of
these devices, especially if the patient does not have health insurance. The cost of the three most
commonly used CGM devices currently on the market, along with their sensor wear time is
shown below in table 1-1 [9].
Sensor wear time

Cost

Penetration layer

(pre-insurance)
Abbott Freestyle

~14 days

$2,300/year

Subcutaneous

Dexcom G6

~10 days

~$3,800/year

Subcutaneous

Medtronic

~7 days

~$4,760/year

Subcutaneous

Libre 2

Guardian Connect
Table 1-1: Current CGM Device Comparison
1.4. Current Issues
As briefly mentioned above, due to the fact that most CGM devices penetrate all the way into the
subcutaneous layer of the skin, many of the users report pain, discomfort, and possible risk of
infection as a result. The inflammatory processes that occur in the local tissue following
implantation can be categorized into three phases: (1) acute inflammatory phase, which invokes
migration of inflammatory cells and plasma proteins toward the site of insertion; (2) intermediate
phases, which invoke phagocytes onto the surface of the implant in an attempt to destroy it; and
(3) chronic inflammatory phase, resulting in the formation of a fibrotic capsule around the
implant (i.e., scarring), lasting from several days to years [10].
As a result of biofouling, approaches to overcome the foreign body reaction have included the
use of biocompatible materials to coat the sensor or reduce the amount of penetration into the
skin.
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Another major issue with the current CGM devices is their cost. Without health insurance, these
devices can be outright too expensive for many families around the world. Paying thousands of
dollars per year for a CGM device, on top of the prices of insulin, can be downright unattainable
for many families.
As a result, in order to make CGM devices more prevalent in our society, they must first be more
affordable and accessible to patients from every socioeconomic background. Furthermore, they
must also reduce the pain and discomfort commonly associated with their usage.
1.5. Project Goal
The focus of this project is to create a minimally invasive continuous glucose monitor, which
penetrates into the dermal layer of the skin for real-time reading of glucose levels. Our goal is to
build a CGM system through the use of 3D printed microneedles, which are able to penetrate a
few hundred micrometers into the skin. Penetrating only into the dermal layer of the skin using
microneedles should reduce the amount of pain and swelling, minimize the risk of infection, and
provide more accurate glucose readings compared to current CGM devices on the market. Unlike
most glucose sensors that measure blood sugar levels, due to the fact that the microneedles will
be designed to penetrate into the dermal layer, it will measure glucose concentration in interstitial
fluid.
We hope that our minimally invasive CGM system will provide diabetic patients with a cheap
and effective alternative for monitoring and managing their blood glucose levels. We believe that
this device will allow diabetic patients to live their lives without pain or swelling and risk of
infection. Also, patients will be able to closely monitor how their glucose levels fluctuate
throughout the day and prepare better treatments to better manage symptoms.
1.6. Literature Review
Continuous glucose monitors are an up-and-coming technology that measures glucose levels in
real-time. Current CGMs penetrate the skin by inserting a needle into the subcutaneous layer of
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the skin and measuring the glucose concentration of the interstitial fluid. These systems utilize
electrochemical reactions consisting of glucose oxidase, the gold standard enzyme for glucose
measuring, and some type of redox mediator. [11]
The three most commonly used CGM devices in the US are Dexcom G6, Freestyle Libre system
from Abbott, and Medtronic’s Guardian Sensor 3 [12]. While these devices are effective in
certain areas of glucose monitoring, they do have some flaws that need to be addressed. The
Dexcom G6 has many advantages, but it can be very costly for users. The Dexcom G6 can cost
upwards of $1,600 per year without health insurance, making it one of the more expensive
options for continuous glucose measurements [13]. The Medtronic Guardian 3 has been shown to
cause pain for patients because it penetrates the subcutaneous layer of the skin [14]. The freestyle
Libre System is not a continuous monitoring system like the other systems listed above. Instead,
the device relies on the user having to scan the sensor for a glucose level reading [13].
This is a continuation of a previous year’s project. The article “Simple and Customizable method
for fabrication of high-aspect-ratio microneedles using low-cost 3D printing”, utilizes a print and
fill method to fabricate microneedle arrays [15]. Through the use of a low-resolution 3D printer
in Dr. Mobed-Miremadi's lab at Santa Clara University, a higher aspect ratio can be achieved.
Needle arrays are fabricated with high resolution by printing with a higher needle height,
shortening needle length by filling the base of the arrays with UV curable resin, and creating a
silicone female mold from the resin-filled arrays.
While the previous group was able to successfully fabricate needle arrays, we believed that we
could improve upon the resolution and needle strength. After performing a literature search, we
found the article “Rapid 3D-print-and-shrink fabrication of biodegradable microneedles with
complex geometries”, which follows a print and shrink method. A 3D printed array is printed
60% bigger than the desired size. Then, an agarose female mold is made from the 3D printed
array and put in an incubator to shrink. Once the shrinking process is done, a 1:10 PDMS
mixture is poured into the shrunken agarose gel to create a new master key. This process is
repeated two more times, however, the agarose gel is not shrunken. Also, PVP is used for the
final needle product [16].

13

In their literature review, they came across a proof-of-concept minimally invasive CGM device
by Ribet, et. al., 2018 [17]. This paper incorporated a three-electrode system circuit model to
continuously monitor glucose concentration in the dermal layer of the skin. As a result, the
previous group also incorporated a three-electrode system. As we performed the commercial
glucose testing, we noticed that the glucose strip implemented a two-electrode system. As a
result, we also implemented a two-electrode system for our microneedle arrays. This
two-electrode system allows for a much more simple electrode manufacturing process while
retaining the ability to detect glucose concentration in a sample.
One of the most important aspects of our CGM device is the fact that it is minimally invasive and
penetrates into the dermal layer. Most current CGM devices penetrate into the subcutaneous
tissue, causing users to feel discomfort, pain, and swelling [18]. This is a potential limitation to
continuous use, as patients may not feel comfortable enough to integrate these devices into their
daily lives. By penetrating only into the dermal layer of the skin, our CGM device will detect
glucose concentration in interstitial fluid, not blood. Blood and interstitial fluid differ in a
number of different aspects with respect to glucose. Interstitial fluid is the compartment in which
substances such as glucose diffuse to the surrounding tissues/cells on a local level; whereas the
bloodstream is the transport system of the body for transporting substances such as glucose over
long distances [19]. Furthermore, interstitial fluid constitutes approximately 45% of the volume
fraction of human skin, with blood vessels contributing 5% of the skin volume [20]. The time
required for glucose to diffuse from the capillary to the tissue plays a vital role in the lag time
between changes in blood plasma glucose levels and interstitial glucose levels.
Under stable conditions blood glucose results and interstitial fluid results show more or less
identical glucose values with rates of change below 1 or 2 mg/dl per min, However, when more
rapid changes in glucose levels are induced, either by exercise, diet, or other activities, glucose
measurements results can differ considerably between blood glucose and interstitial fluid [19].
Due to these discrepancies, patients using CGM systems are required to perform blood glucose
measurements to make their therapeutic decisions (insulin dose adjustments).
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Generally, glucose measurements are based on interactions with hexokinase, GOx, or
glucose-1-dehydrogenase [21]. The first generation of glucose biosensors was first proposed in
1962 by Clark and Lyons from the Children’s Hospital of Cincinnati [22]. This glucose sensor
utilized GOx immobilized in a polyacrylamide gel on an oxygen electrode [23].
Second-generation glucose biosensors replaced oxygen with non-physiological electron
acceptors such as ferrocene, ferricyanide, methylene blue, and other electron mediators [24].
Third-generation glucose sensors are reagentless and based on direct contact between the enzyme
and the electrode without any intermediate mediators. Therefore, third-generation glucose
biosensors have led to the development of implantable, needle-based devices for continuous
monitoring of glucose in vivo [25],[26]. Consequently, our CGM device is based on a
third-generation glucose biosensor that uses different metal coatings which interact directly with
enzymes to detect glucose concentration in interstitial fluid.
1.7. Significance
The purpose of our project is to create a more affordable, accessible, and effective option for
patients to better understand and manage their diabetes. This system would give patients the
ability to access real-time blood glucose measurements and predict the direction their glucose
levels are trending.

Chapter 2: Design Description
2.1. Solid Microneedles Design
Based on the previous group’s data, we decided to move forward with the 4.5:1 aspect ratio in a
5x5 array [15]. Due to our print and shrink method, we decided to increase the size of our
microneedle arrays by sixty percent compared to the previous group's models. The width, length,
and needle heights came out to be 24mm, 24mm, and 4.5mm respectively. An image of the
updated array on SolidWorks can be seen below in Figures 1-2. Our SolidWorks files were
printed using an SLA 3D printer (Formlabs Form2 Rapid Prototyping Machine) and used for our
two fabrication methods.
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Figure 1-2: Solidworks Model of Microneedle Array
2.2. Glucose Oxidase Reaction
Glucose Concentration sensing on the solid microneedles will be conducted using a
two-electrode system and via the glucose oxidase (GOx) reaction shown in equation 1

Equation 1: Glucose Oxidase Reaction
In this reaction, glucose is oxidized in the presence of oxygen, water, and GOx. This reaction
forms gluconic acid and hydrogen peroxide. The hydrogen peroxide is then subsequently
electrochemically oxidized at the working electrode, which produces a current proportional to
the concentration of glucose in the sample, as seen by the 2 electrons produced in red.
This redox reaction will be utilized to compare the measurements from our microneedle array
system using the electrochemical analyzer, compared to commercially available glucose meters
in order to analyze the accuracy and precision of our system.
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2.3. Two Electrode System
For our electrode system, we decided to implement a two-electrode system based on current
commercial glucose sensors and for ease of fabrication. For the working electrode, we used
carbon conductive paint. Since we decided to implement a two-electrode system, we combined
the working and reference electrode and used a silver/silver chloride (60/40) paste. The purpose
of each electrode is described in tables 2-1 down below.

Working

Reference

Counter

* Where the reaction of
interest takes place

* Has a well-known electrical
potential used to determine
the potential of the working
electrode

* Source of electrons for the
reaction occurring in working
electrode

* Magnitude of current
reveals the concentration of
analyte (Glucose)

* No current flows through

* Current flows through the
counter electrode to
compensate for opposite
current flowing through
working electrode

* Coated with silver/silver
chloride paste

* Coated with silver
conductive paint

* Reference electrode stays in
chemical equilibrium

* Carbon Conductive paint

Table 2-1: Electrode Description
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Chapter 3: Methods, Results, and Materials
3.1.1 Print and Fill Fabrication of Microneedles
Using a gray UV curable resin, we filled up the microneedle array basin to the top of the basin
wall so that only 1mm needles were exposed at the top of the resin. Next, we dip-coated the
needles in Inhibit X in order to protect against cure inhibition and sprayed the exposed needles
with Mann Ease Release 200.
We then prepared our Silicone mold casting that was used to create a female mold of our
microneedle arrays. We mixed a set of platinum silicone medium cure rubber agents at a ratio of
1:1. Depending on how many molds you are making at once, we typically went with 7.5g of each
silicone solution. We then set our microneedle array onto a small plate and carefully poured the
silicone rubber mix so that it completely covered the microneedle array basin. After degassing
our needles for at least 24 hours, we peeled off the female mold from our microneedles.
The resulting female mold has holes according to the 1mm exposed needle array. We then
created a solution of 5%(w/v) sodium carboxymethyl cellulose to DI water, mixed the solution
using a vortex mixer, and left it in a heated 60˚C water bath for an hour. After, we added
bromophenol blue dye to the solution, mixed it again with a vortex mixer, and let it sit in a 60˚C
water bath for another hour. Finally, we poured the solution onto the female molds, and after
about 48 hours, the solution dried within the mold, and we obtained our final fabricated
microneedles. An illustration of the print and fill method is shown below in figure 3-1 [15].
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Figure 3-1: Print and Fill Method
3.1.2. Print and Fill Results
In our first attempts at fabricating the carboxymethyl cellulose solution, we noticed we weren’t
getting the gelatinous consistency we were expecting. Instead, we were left with a thin liquid
solution that led to a very thin and brittle-like final product as seen in figures 3-2.

Figure 3-2: First Carboxymethyl Cellulose Solution
One possible reason, which was later improved upon, was the need to have a magnetic stirrer in
the beaker when placed in the hot water bath. This allowed for better mixing of the solution and
gave us the right consistency we were looking for.
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After making some adjustments to our carboxymethyl cellulose fabrication process, we
proceeded with making the final needle array products. The new carboxymethyl cellulose
solution resulted in more defined needle arrays. However, upon careful removal from the silicone
mold, we noticed that the structural integrity of the needles was compromised because the
material was very fragile. Another issue with the print and fill method was the short shelf life as
the needle arrays shrunk and shriveled up into an unusable product as seen in Figures 3-3.

Figure 3-3: Second Carboxymethyl Cellulose Attempt
One possible reason for the fragile final product was the cellulose solution was not completely
mixed. When placing the cellulose in the water bath to mix, the temperature fluctuated between
45-60˚C. This could have affected the mixing between the water and carboxymethyl cellulose
solution. While we did get the right consistency, we believe that leaving the solution in the water
bath for a longer time could have led to a better-mixed solution. Also, using a more consistent
hot plate could have improved our results.
3.2.1 Print and Shrink Fabrication of Microneedles
We used a stereolithography (SLA) 3D printer (Formlabs Form2 Rapid Prototyping Machine)
using UV curable resin (White Resin V4, Formlabs Inc., Somerville, MA, USA) to fabricate our
initial set of microneedles. When using an SLA 3D printer, there are inherent limitations with the
resolution of the geometric structures which are 3D printed [27]. Due to these limitations of
using a 3D printer for the generation of microneedles, there is a need to increase the resolution of
the structures printed so that they are capable of puncturing into the skin.
20

The “Print and Shrink” method was developed by M. Ochoa, et al., 2015 as a way to develop a
simple technique for fabricating microneedles of complex geometric shapes [16]. This method
consists of transferring the pattern of 3D printed microneedles to a negative hydrogel mold,
which is then subsequently shrunk by up to 40% within 12 hours. After the desired
shrinkage/refinement is achieved, new needle patterns are then transferred to a biodegradable
polymer, resulting in microneedles that are sufficiently sharp to penetrate porcine skin.
Figure 3-4 illustrates the “Print and Shrink” fabrication process for creating a set of microneedle
arrays. First, the needle array is designed in SOLIDWORKS and fabricated by SLA 3D printing.
This 3D printing process produces deposits on the object which are then subsequently dissolved
by soaking the microneedle array in a 1 M NaOH solution for 24 hours under continuous stirring
at 250 rpm. The microneedle array is then placed face up in a petri dish and the pattern is
transferred to hydrogel by casting 1.5% w/v agarose onto the mold. After 30 minutes, the 3D
printed microneedles are then removed from the hydrogel. The negative hydrogel mold is then
sandwiched between two layers of agarose gel to form a protective layer to prevent aspect ratio
distortions during the subsequent shrinking process. Next, shrink the hydrogel mold via
evaporation in an oven set for 70˚C for 10 hours (Adjust shrinking time depending on the size of
the hydrogel mold).
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Figure 3-4: Print and Shrink Method
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Remove the hydrogel mold from the oven and use it as a mold for transferring the microneedle
array pattern to PDMS (polydimethylsiloxane, 10:1 Ratio, Sylgard 184, Dow Corning). Prepare
the PDMS separately and degas for 15 minutes. Then, pour the 10:1 PDMS onto the negative
hydrogel mold in a petri dish, degas for an additional 15 minutes, then incubate at 80˚C for 2.5
hours. The new PDMS needles are then sharpened by dipping them in a silicone-dissolving
solvent (Dynasolve 218, Dynaloy LLC, Indianapolis, IN, USA) for 6 minutes. Further shrinkage
can be achieved if the process is repeated. Figure 3-5.

Figure 3-5: PDMS Needle Array
3.2.2 Print and Shrink Fabrication Results
While fabricating microneedles using the “Print and Shrink” fabrication method, we only made it
to the first PDMS microneedles step. The PDMS step was largely inconsistent with the transfer
of the microneedle array patterns. As shown in figure 3-6 and figure 3-7 below, not all
microneedles were successfully transferred into a PDMS mold.
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Figure 3-6: Successful microneedle pattern transfer to PDMS mold

Figure 3-7: Unsuccessful microneedle pattern transfer to PDMS mold
One possible reason for this inconsistency can be due to the inconsistent shrinking rate
experienced during the evaporative shrinking process. The paper by M. Ochoa, et al., 2015 was a
conference paper, which means its method section was not as descriptive as an ordinary literature
article. The fabrication method of the protective layer required for preventing aspect ratio
distortion during the shrinking process was not very descriptive. As a result, it was difficult to
completely replicate their results.
Another possible reason for the inconsistent microneedle array pattern transfer to a PDMS mold
could be damaging the PDMS needles while the user is removing them from the negative
hydrogel mold. When removing the PDMS needles from the negative hydrogel mold, if
performed without caution, parts of the PDMS needles may break inside the negative hydrogel
mold, leading to the results shown in Figure 3-7.
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3.3. Electrode Fabrication
Our CGM system implements a 2 electrode system to perform glucose level monitoring in the
dermal layer. The working electrode consists of a carbon conductive paint layer, while the
reference/counter electrode consists of silver conductive paint.
Once your final needle product is obtained from either the “Print and Shrink” or “Print and Fill”
method, pipette a small layer of carbon conductive paint onto two rows of the 5x5 microneedle
array. Next, pipette a small amount of silver conductive paint onto the opposite 2 rows of the
microneedle array, leaving a bare middle row with no metallic coating as shown in Figure 3-8.

Figure 3-8: Electrode fabrication onto microneedle array
While the metal coatings are drying onto the microneedles, place electrically conductive wires
onto the electrodes while making sure there is sufficient contact between the wire and metal
coating to allow for optimal conductivity. Figure 3-9 shows the product after microneedle array
fabrication after electrode fabrication
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Figure 3-9: Final microneedle array after electrode fabrication

3.4 Materials
Commercial Glucose Meter (Keto Mojo Glucose Meter), Digital Microscope (Bysameyee USB
Digital Microscope 40X to 1000X), Glucose (from Sigma Aldrich), PBS (from Alumni Science
lab), Bromophenol Blue Dye (from Sigma Aldrich), DI water, Conductive Paste (Silver/Silver
Chloride Paste from Sigma Aldrich), Mann Ease Release (Mann Release Technologies Ease
Release 200 14 fl. oz.), Platinum Cure Silicone Rubber (Smooth-On Dragon Skin 10 Medium
platinum cure silicone rubber), Inhibit X (from ReynoldsAM), UV-curable Resin (Crystal Clear
Ultraviolet Curing Epoxy Resin for DIY Jewelry Making, Craft Decoration from Youngfocus),
Rich-OPTO 3D Printer Resin UV-Curing 405nm Rapid High Precision Quick Curing Standard
Glucose Test Strips (bkt Glucose Test Strips (x200)), Platinum Wire (PT005115 Platinum Wire
from Goodfellow), Silver Spray Paint (MG Chemicals 842AR-140G Super Shield Silver
Conductive Coating, 5 oz, Aerosol Can), Carbon Spray Paint (MG Chemicals - 838AR-340G
838AR Total Ground Carbon Conductive Paint, 12 oz Aerosol Spray Can), Silver Liquid Paint
(MG Chemicals 842-20G Silver Print Conductive Liquid Paint, 20g Container), Transfer Pipettes
(from Karter Scientific 206H3), Dynaloy Dynasolve 218 Cleaner Light Amber 1 Qt Bottle.
The costs and vendors for each item listed above can be found in figure 5-1in the Cost analysis
section
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Chapter 4: Glucose Testing
4.1. Commercial Glucose Testing
The accuracy of blood glucose meters is important for the calculation of insulin doses and the
calibration of continuous glucose monitors. A study by Laya Ekhlaspour, et al., 2017, has shown
that across 17 commercially available glucose meters from 9 different manufacturers, the
accuracy across a wide range of glucose levels varies widely [28]. In order to test the accuracy of
a commercial glucose sensor, we tested AUVON’s blood sugar test kit. We tested values from
50-350 mg/dl in increments of 30 mg/dl. After conducting three separate readings for each
concentration, we plotted the measured glucose concentration vs. expected glucose
concentration. The resulting R-squared value represents the proportion of the variance for a
dependent variable that’s explained by an independent variable or variables [29]. As seen in
figure 4-1, the R-squared value = .996, showing that the AUVON commercial glucose meter is
accurate.

Figure 4-1: R^2 value of AUVON commercial glucose sensor
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4.2. Auvon Commercial Glucose Testing with Electrochemical Analyzer
After the accuracy of the commercially available AUVON glucose meter was shown, a series of
glucose testing was performed using a CHI 730D electrochemical analyzer (CHI Co., USA).
These sensor strips implement a two-electrode system and thus needed an edge board connector
in order to test using the CHI instrument, we used the CONN EDGE SGL FEMALE 10POS
0.156 connector from Digi-key (Digi-Key Co., USA) shown in figure 4-2.

Figure 4-2: Female edge adaptor for two-electrode glucose sensor
Electrochemical analysis was performed from a range of different predetermined concentrations
of glucose in 10X PBS solution. Amperometry was used to quantitatively determine current peak
values and trends which correspond to different glucose concentrations through the usage of the
glucose oxidase reaction.
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Enzymatic amperometric glucose biosensors are the most common devices commercially
available. Amperometric sensors monitor currents generated when electrons are exchanged either
directly or indirectly between a biological system and an electrode [30]. In an amperometric
glucose sensing technique, glucose values are estimated by measuring the electrical current
generated by the reaction of glucose with an immobilized redox mediator, in this case, glucose
oxidase [31]. There are generally three enzymes used for glucose measurements: hexokinase,
GOx, or glucose-1-dehydrogenase (GDH) [32],[33]. We chose to use GOx because it has a
relatively higher selectivity for glucose, is easy to obtain, relatively cheap, and can withstand
greater extremes of pH, ionic strength, and temperature than many other enzymes. These
conditions allow for less stringent conditions during the manufacturing process and relatively
relaxed storage norms [34],[35]
Using the CHI instruments 730D we performed amperometric detection for glucose ranges from
50-140 mg/dl in increments of 30 mg/dl using the AUVON glucose testing strips. We used an
initial voltage of 0.6V, a scan rate of 0.1 V/s, a sampling rate of 5 seconds, and a sensitivity of
1e-004. Figure 4-3 shows that as the glucose concentration increases, so does the maximum
current output.

Figure 4-3: Results of AUVON commercial glucose sensor with electrochemical analyzer
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4.3. Dropsens Glucose Testing
Before testing our microneedles, we wanted to mimic the conditions on our microneedles onto an
electrode strip. For this testing, we used Metrohm Dropsens 110 testing strips which implement a
three-electrode system. The working electrode consists of carbon, the counter electrode also
consists of carbon, and the reference electrode consists of silver. Unlike other glucose sensors,
Metrohm’s Dropsens sensor does not have GOx predeposited, as a result, GOx needs to be
deposited onto the working, counter, and reference electrode.
We wanted a 50u/uL solution of GOx, so we measured out .0063 grams for every 200uL of 10x
PBS solution. A stock solution of 10% glutaraldehyde was diluted to the desired 2% via a 5x
dilution. 40ul of the 10% was mixed with 160ul of DI water to create the 2% solution. The
diluted Glutaraldehyde solution (2%) was mixed with GOx (Toyobo Ltd., Toyobo) solution (50
U/ul) at a volume ratio of 1:2 respectively. Then 20 ul of the Glutaraldehyde + GOx mixture was
deposited on the working electrode. 20ul of this GOx + glutaraldehyde solution was then
pipetted onto the working electrode of the Metrohm Dropsens sensor.

Figure 4-4: GOx deposited onto electrodes of Metrohm Dropsens 110

30

Next, 30ul of the predetermined glucose solutions (40-160 mg/dl; increments of 40 mg/dl) were
pipetted onto the GOx + glutaraldehyde mixture and gently pipette mixed on the working
solution as shown in figure 4-4.
After running the CHI 730 instrument for the specified glucose concentrations shown in table
4-5, it is apparent that as the glucose concentration increases, so does the maximum current
output shown in figure 4-6.

Table 4-5: Glucose concentrations tested and the maximum current output for each respective
concentration

Figure 4-6: Graph overlay of electrochemical analyzer results using Dropsens 110
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4.4.1 Microneedle Array Glucose Testing
After painting our final needle arrays, we were able to proceed with glucose testing using a
similar procedure as the DropSens method above. We wanted a 50u/uL solution of GOx, so we
measured out .0063 grams for every 200uL of 10x PBS solution. A stock solution of 10%
glutaraldehyde was diluted to the desired 2% via a 5x dilution. 40ul of the 10% was mixed with
160ul of DI water to create the 2% solution. The diluted Glutaraldehyde solution (2%) was
mixed with GOx (Toyobo Ltd., Toyobo) solution (50 U/ul) at a volume ratio of 1:2 respectively.
Then 20 ul of the Glutaraldehyde + GOx mixture was deposited on the working and
reference/counter electrodes [36]. 20ul of this GOx + glutaraldehyde solution was then pipetted
onto the working and counter/reference electrodes.
Next, 30ul of the predetermined glucose solutions (40-160 mg/dl; increments of 40 mg/dl) were
pipetted onto the GOx + glutaraldehyde mixture and gently pipette mixed on the microneedle
array.
4.4.2 Microneedle Array Glucose Testing Results
After running tests for each concentration level (40-160 mg/dL), we received the results as seen
in figure 4-7 down below. We noticed that the maximum current, which is used to quantify the
amount of glucose concentration in each solution, did not follow the trendline that we expected.
As our concentration increases, we would expect to see the maximum current increase as well.
However, this was not the case for our experiments as the maximum current values fluctuated
throughout our experiment.
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Figure 4-7: Electrochemical analyzer results from microneedle array glucose testing

Chapter 5: Cost Analysis
Figure 5-1: Component list and order cost
Component

Total Number

Vendor

SKU number

Order Cost*

1

Amazon

DS-W5050011

$22.93

1

Amazon

B07SR7YPV5

$24.02

of Units
Commercial
Glucose Meter
AUVON DS-W
Blood Sugar Kit

Digital
Microscope
Bysameyee
USB Digital
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Microscope
40X to 1000X

Conductive

1

Sigma-Aldrich

901773-50G

$283.66

1

Amazon

B002YEBO1O

$22.37

1

Reynolds

Inhibit X

$72.15

Paste
Silver/Silver
Chloride Paste

Mann Ease
Release Mann
Release
Technologies
Ease Release
200 14 fl. oz
Inhibit X

Advanced
Materials
Silver Liquid

1

Amazon

842-20G

$53.00

1

Electronic

842AR-140G

$145.34

Paint MG
Chemicals
842-20G Silver
Print
Conductive
Liquid Paint,
20g Container

Silver Spray

Inventory

34

Paint

MG

Online

Chemicals
842AR-140G
Super Shield
Silver
Conductive
Coating, 5 oz,
Aerosol Can

polydimethylsil

1

Amazon

184

$165.00

100g

Sigma-Aldrich

PVP10-100G

$49.00

1 Quart

Ellsworth

DYNASOLVE

$243

oxane, 10:1
ratio, Sylgard®
184, Dow

PVP10-100G

Dynasolve 218

Glucose Oxidase 60kU

218
Sigma-Aldrich

from Aspergillus
niger,Type X-S,
lyophilized
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G7141-50KU

$160.30

powder
Edgeboard

5

Digikey

151-1341-ND

$23.90

Connector

Chapter 6: Professional Issues and Constraints
6.1. Ethical
As this medical device continues to develop and potentially be implemented for commercial use,
there are a few ethical considerations that we must account for. One of the more important
considerations is the accessibility and affordability of the device. Current CGMs can be very
costly and hard to access for families in a lower financial bracket, making it important to create a
more affordable device that is easily accessible to all diabetic patients.
6.2. Health and Safety
One of the issues with current CGM devices is that they need to penetrate the subcutaneous layer of the
skin, causing increased pain and swelling upon penetration. Our sensing device hopes to penetrate into the
dermal layer, one level higher than the subcutaneous, in order to make life easier for users. Another factor
to take into account is that the materials used to fabricate the device must be biocompatible since the
device will be inside the skin for up to 14 days at a time. Research will need to be done to ensure that the
device is not toxic and cause any further damage or irritation to the skin upon penetration. The needle
array must also be sterilized before use to minimize the risk of infections. It is also important to make sure
the users are not exposed to any dangerous current levels in case the device malfunctions.

6.3. Environmental Impact
The environmental impact of this device can be applied to fabrication and disposal methods. The use of
3D-printed needle arrays eliminates the waste of materials compared to other techniques that require
polishing or edging. The material used for the printing of our needle arrays, Polylactic Acid (PLA), is
derived from renewable resources and is biodegradable within 6-9 months.
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For the print and fill method, silicone was used to create a negative mold of the 3D printed arrays. While
silicone is not biodegradable, it is incredibly durable and can be used multiple times. For the final
product, carboxymethyl cellulose was used. This material is a biodegradable polysaccharide that does not
cause any harm to the environment.
For the print and shrink method, we use an agarose gel to create a negative mold of the 3D printed
microneedle array. PDMS was used for the final product

6.4. Science, Technology, and Society
This device will give diabetic patients a more affordable, easy-to-use alternative for continuous glucose
monitoring. The potential of this device can give patients, physicians, and researchers a better
understanding of how diabetes affects each individual by providing more data for analysis. This should
allow for physicians to prepare better treatments for their patients and minimize the amount of doctor
appointments for the patient. Having the ability to continuously monitor glucose levels can give patients a
better understanding of how their daily routines, exercise, and glucose levels are affected throughout the
day. Furthermore, this device can improve healthcare systems in underdeveloped countries with little to
no resources.

Chapter 7: Summary and Conclusions
7.1. Conclusions
In conclusion, our project focused on fabricating a glucose monitor that could continuously
monitor one’s glucose levels, which in turn can lead to better lives for diabetic patients. Allowing
patients and physicians to track glucose levels throughout the day can lead to better treatments
and lifestyle changes. We were able to fabricate a solid microneedle array using two different
methods and implement a two-electrode system to measure various glucose levels. The
fabrication of the needles has the potential to make continuous glucose monitoring more
accessible, easy to use, and less invasive for diabetic patients.
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7.2. Future Works
Although we were able to produce successful microneedle arrays, our procedure was inconsistent. Some
possible causes for this were the 3D printed needle array dimensions and the agarose “sandwich” used
during the shrinking process. We believe that by increasing the dimensions of the 3D printed arrays, the
PDMS needles will be more defined and consistent.
Another area to work on is the fabrication of the electrode system. The carbon paint was very thin which
made it difficult to apply and keep a conductive wire on the array. Researching a different carbon
conductive paint would be the next step to optimizing the fabrication of the electrode system.
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